Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated With Infectious Systemic Inflammatory Response Syndromes

Journal of Clinical Medicine
doi 10.3390/jcm8101553
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Benefit Profile of Recombinant Human Soluble Thrombomodulin in Sepsis-Induced DIC

Critical Care
Critical CareIntensive Care Medicine
2014English

Phase I Study of Solulin, a Novel Recombinant Soluble Human Thrombomodulin Analogue

Thrombosis and Haemostasis
Hematology
2011English

Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy

JAMA - Journal of the American Medical Association
Medicine
2019English

Clinical Outcomes of Recombinant Human-Soluble Thrombomodulin Treatment for Disseminated Intravascular Coagulation in Solid Tumors

Anticancer Research
MedicineCancer ResearchOncology
2019English

Drug-Induced Thrombotic Thrombocytopenic Purpura Successfully Treated With Recombinant Human Soluble Thrombomodulin

Internal Medicine
Internal MedicineMedicine
2013English

Soluble Siglec-8 Levels Are Detectable in Subjects With Myeloid Variant Hypereosinophilic Syndromes, but Not in Those With D816V KIT + Systemic Mastocytosis

Journal of Allergy and Clinical Immunology
AllergyImmunology
2018English

Enhanced Effect of Recombinant Human Soluble Thrombomodulin by Ultrasound Irradiation in Acute Liver Failure

Scientific Reports
Multidisciplinary
2020English

The Systemic Inflammatory Response in the Development of Ventilator-Associated Pneumonia

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
1997English

Erratum to “Postpercutaneous Nephrolithotomy Systemic Inflammatory Response Syndrome Is Not Associated With Unplanned Readmission”

Urology
Urology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy